Alliances
The Ministry of Health and Prevention recently organized a community awareness event to celebrate World Food Day in collaboration with the College of Health Sciences - Nutrition Department of the University of Sharjah held under the theme of ‘Healthy diet and cooking.’
Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.
IntegraGen today announced it will be collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform.
Medical imaging manufacturer Planmed and med tech startup Disior are bringing next-generation medical image analysis software into clinical use. “Until today, 3D medical images have been analyzed using 2D slices, as if you were looking at the image with one eye only,” says professor and orthopedic surgeon Jari Salo.
Polarean Imaging plc provides shareholders with the following update on Company progress
GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology
AusCann appoints TGA licensed PCI Pharma to manufacture and release its first medicinal cannabis product line.
Germany’s pharma giant Merck KGaA, Darmstadt, Germany and Silicon Valley data analytics company Palantir Technologies are forming a joint venture called Syntropy. Syntropy will be based in Boston and will focus on cancer data analytics tools.
Under the terms of the deal, Roivant is paying iNtRON Bio $10 million upfront. iNtRON will be eligible for milestone payments. When the first patient receives treatment in a U.S. Phase II clinical trial scheduled for 2019, the first milestone will be $30 million.
Denmark-based LEO Pharma and California rare disease drugmaker PellePharm entered into a strategic collaboration worth $760 million to address unmet needs in multiple orphan skin diseases, such as Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), two rare forms of skin cancer.
PRESS RELEASES